ATE144281T1 - Hefezellen der gattung-schwanniomyces - Google Patents

Hefezellen der gattung-schwanniomyces

Info

Publication number
ATE144281T1
ATE144281T1 AT89107780T AT89107780T ATE144281T1 AT E144281 T1 ATE144281 T1 AT E144281T1 AT 89107780 T AT89107780 T AT 89107780T AT 89107780 T AT89107780 T AT 89107780T AT E144281 T1 ATE144281 T1 AT E144281T1
Authority
AT
Austria
Prior art keywords
dna sequence
yeast cells
genus schwanniomyces
expression
optionally
Prior art date
Application number
AT89107780T
Other languages
English (en)
Inventor
Cornelius P Prof Dr Hollenberg
Alexander Dr Strasser
Original Assignee
Rhein Biotech Proz & Prod Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhein Biotech Proz & Prod Gmbh filed Critical Rhein Biotech Proz & Prod Gmbh
Application granted granted Critical
Publication of ATE144281T1 publication Critical patent/ATE144281T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
AT89107780T 1989-04-28 1989-04-28 Hefezellen der gattung-schwanniomyces ATE144281T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP89107780A EP0394538B1 (de) 1989-04-28 1989-04-28 Hefezellen der Gattung-Schwanniomyces

Publications (1)

Publication Number Publication Date
ATE144281T1 true ATE144281T1 (de) 1996-11-15

Family

ID=8201308

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89107780T ATE144281T1 (de) 1989-04-28 1989-04-28 Hefezellen der gattung-schwanniomyces

Country Status (7)

Country Link
EP (1) EP0394538B1 (de)
JP (1) JPH03143385A (de)
AT (1) ATE144281T1 (de)
CA (1) CA2015077C (de)
DE (2) DE68927344T2 (de)
ES (1) ES2038579T3 (de)
GR (2) GR910300058T1 (de)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2107041T3 (es) 1992-06-03 1997-11-16 Genentech Inc Variantes de activador de plasminogeno tisular obtenidos por glicosilacion, que presentan propiedades terapeuticas.
ES2202469T5 (es) 1995-09-08 2011-06-06 Genentech, Inc. Proteína relacionada con el vegf.
DE69734443T2 (de) 1996-01-08 2006-07-13 Genentech, Inc., South San Francisco Ob-rezeptor und liganden
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6265186B1 (en) 1997-04-11 2001-07-24 Dsm N.V. Yeast cells comprising at least two copies of a desired gene integrated into the chromosomal genome at more than one non-ribosomal RNA encoding domain, particularly with Kluyveromyces
EP2033970A3 (de) 1997-10-29 2009-06-17 Genentech, Inc. WNT-1-induzierbare Gene
DE69839942D1 (de) 1997-10-29 2008-10-09 Genentech Inc Verwendung des wnt-1 induzierten sekretierten polypeptids wisp-1
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
EP1076703B2 (de) 1998-05-15 2010-12-15 Genentech, Inc. Therapeutische verwendungen von il-17 homologe polypeptide
EP1865061A3 (de) 1998-05-15 2007-12-19 Genentech, Inc. IL-17-homologe Polypeptide und ihre therapeutische Verwendung
EP3112468A1 (de) 1998-05-15 2017-01-04 Genentech, Inc. Il-17-homologe polypeptide und therapeutische verwendung davon
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
EP1484338B1 (de) 1998-12-22 2007-02-07 Genentech, Inc. Verfahren und Zusammensetzung zur Hemmung des neoplastischen Zellwachstums
DE60043322D1 (de) 1999-06-15 2009-12-24 Genentech Inc Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
CA2490853A1 (en) 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1897945B1 (de) 1999-12-23 2012-01-18 Genentech, Inc. IL-17-homologe Polypeptide und ihre therapeutische Verwendung
CN1425066B (zh) 2000-01-13 2010-05-26 杰南技术公司 新的stra6多肽
WO2004043361A2 (en) 2002-11-08 2004-05-27 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
EP2792747A1 (de) 2000-06-23 2014-10-22 Genentech, Inc. Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
EP2168980A1 (de) 2000-06-23 2010-03-31 Genentech, Inc. Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
ATE412009T1 (de) 2000-08-24 2008-11-15 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
EP1944317A3 (de) 2000-09-01 2008-09-17 Genentech, Inc. Sekretierte und Transmembran-Polypeptide sowie Nukleinsäure zu deren Kodierung
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
EP2000148A1 (de) 2001-06-20 2008-12-10 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Prostatakarzinom
KR101008785B1 (ko) 2001-08-29 2011-01-14 제넨테크, 인크. 유사분열촉진 활성을 가진 Bv8 핵산 및 폴리펩티드
NZ531674A (en) 2001-09-18 2009-03-31 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
PT2279753E (pt) 2001-10-10 2016-01-15 Novo Nordisk As Remodelação e glicoconjugação de péptidos
EP2305311A3 (de) 2001-10-10 2011-07-20 BioGeneriX AG Glykokonjugation von Peptiden
EP2067472A1 (de) 2002-01-02 2009-06-10 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
EP2388265A1 (de) 2002-02-22 2011-11-23 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung von Immunerkrankungen
NZ535925A (en) 2002-04-16 2008-06-30 Genentech Inc An isolated antibody that binds to a particular polypeptide
EP2305710A3 (de) 2002-06-03 2013-05-29 Genentech, Inc. Synthetische Antikörperphagenbibliotheken
MXPA04012243A (es) 2002-06-07 2005-02-25 Genentech Inc Composiciones y metodos para l diagnostico y tratamiento de tumores.
AU2003247806B2 (en) 2002-07-08 2009-11-12 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1539228B1 (de) 2002-09-11 2010-12-29 Genentech, Inc. Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
JP2006521082A (ja) 2002-09-11 2006-09-21 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
WO2004024862A2 (en) * 2002-09-13 2004-03-25 Wockhardt Limited Yeast protein expression secretion system
EP2444409A2 (de) 2002-09-16 2012-04-25 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung von Immunerkrankungen
US20070042945A1 (en) 2002-09-25 2007-02-22 Genentech, Inc. Nouvelles compositions et methods de traitement du psoriasis
AU2003298607B9 (en) 2002-10-29 2011-08-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2311868A1 (de) 2002-11-26 2011-04-20 Genentech, Inc. Zusammensetzung und Verfahren zur Behandlung von Immunerkrankungen
WO2004065417A2 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
EP1615659B1 (de) 2003-03-12 2014-04-16 Genentech, Inc. Verwendung von bv8 und/oder eg-vegf zur förderung der hematopoiese
ES2349779T5 (es) 2003-04-04 2013-11-26 Genentech, Inc. Formulaciones de anticuerpos y de proteínas a concentración elevada
CA2522345A1 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
CA2528591C (en) 2003-06-12 2013-01-08 Eli Lilly And Company Glp-1 analog fusion proteins
CA2530284A1 (en) 2003-07-08 2005-02-03 Genentech, Inc. Il-17 a/f heterologous polypeptides and therapeutic uses thereof
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
ES2472690T3 (es) 2003-11-17 2014-07-02 Genentech, Inc. Anticuerpo contra CD22 para el tratamiento de tumores de origen hematopoy�tico
CA2610709A1 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
EP1995321A2 (de) 2005-08-15 2008-11-26 Genentech, Inc. Neuartige Genunterbrechungen, dazugehörige Zusammensetzungen und Verfahren in Zusammenhang damit
EP1962584A2 (de) 2005-11-21 2008-09-03 Genentech, Inc. Neuartige genunterbrechung, dazugehörige zusammensetzungen und verfahren
WO2007114979A2 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
WO2007109376A2 (en) 2006-03-23 2007-09-27 Novartis Ag Anti-tumor cell antigen antibody therapeutics
EP2007428A2 (de) 2006-04-05 2008-12-31 Genentech, Inc. Verfahren zur verwendung von boc/cdo zur modulation der hedgehog-signalisierung
WO2008036437A2 (en) 2006-04-19 2008-03-27 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
CA2652452C (en) 2006-05-15 2018-07-31 Sea Lane Biotechnologies, Llc Neutralizing antibodies to influenza viruses
WO2007149567A2 (en) 2006-06-21 2007-12-27 Musc Foundation For Research Development Targeting complement factor h for treatment of diseases
SG176476A1 (en) 2006-11-02 2011-12-29 Daniel J Capon Hybrid immunoglobulins with moving parts
KR101508397B1 (ko) 2007-02-22 2015-04-08 제넨테크, 인크. 염증성 장 질환의 검출 방법
SG10202005450PA (en) 2007-07-09 2020-07-29 Genentech Inc Prevention of disulfide bond reduction during recombinant production of polypeptides
EP2641618A3 (de) 2007-07-16 2013-10-23 Genentech, Inc. Humanisierte Anti-CD79b Antikörper und Immunkonjugate sowie Verwendungsverfahren
PL2474557T3 (pl) 2007-07-16 2015-02-27 Genentech Inc Przeciwciała anty- CD79b i immunokoniugaty i sposoby stosowania
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术(上海)有限公司 白介素-22在治疗脂肪肝中的应用
TWI640535B (zh) 2008-01-31 2018-11-11 建南德克公司 抗-cd79b抗體及免疫共軛物及使用方法
AU2009228058A1 (en) 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to viral antigens
EP3208612B1 (de) 2008-04-09 2019-09-18 Genentech, Inc. Zusammensetzungen und verfahren zur behandlung von immunbedingten erkrankungen
US8937046B2 (en) 2008-09-22 2015-01-20 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
HUE031840T2 (en) 2009-02-03 2017-08-28 Amunix Operating Inc Longer recombinant polypeptides and compositions containing them
EP2414399A1 (de) 2009-04-01 2012-02-08 F. Hoffmann-La Roche AG Anti-fcrh5-antikörper und immunkonjugate und anwendungsverfahren
JP5839597B2 (ja) 2009-06-08 2016-01-06 アムニクス オペレーティング インコーポレイテッド グルコース調節ポリペプチド並びにその作成及び使用方法
CN103140236B (zh) 2009-06-08 2017-04-19 阿穆尼克斯运营公司 生长激素多肽及其制备和使用方法
JP6016636B2 (ja) 2009-10-15 2016-10-26 ジェネンテック, インコーポレイテッド 改変したレセプター特異性を持つキメラ線維芽細胞増殖因子
KR20120105446A (ko) 2009-10-22 2012-09-25 제넨테크, 인크. 대식세포-자극 단백질의 헵신 활성화를 조정하기 위한 방법 및 조성물
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
JP2013510871A (ja) 2009-11-12 2013-03-28 ジェネンテック, インコーポレイテッド 樹状突起棘の密度を促す方法
RU2015132142A (ru) 2009-11-30 2015-12-20 Дженентек, Инк. Композиции и способы для диагностики и лечения опухоли
CA2787657A1 (en) 2010-02-23 2011-09-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2793544A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
ES2690760T3 (es) 2010-06-25 2018-11-22 Inserm - Institut National De La Santé Et De La Recherche Médicale Polipéptido de flagelina como agonista de TLR5 para su uso en el tratamiento de infecciones de las vías respiratorias
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术(上海)有限公司 白介素-22在治疗病毒性肝炎中的应用
CA2811403A1 (en) 2010-09-15 2012-03-22 Aligna Technologies, Inc. Bioproduction of aromatic chemicals from lignin-derived compounds
EP2640831A1 (de) 2010-11-17 2013-09-25 Sea Lane Biotechnologies,llc. Die bindungsstelle eines influenzaneutralisierenden antikörpers nachahmende influenzavirusneutralisierungsmittel
US11220556B2 (en) 2013-03-15 2022-01-11 Biomolecular Holdings Llc Hybrid immunoglobulin containing non-peptidyl linkage
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术(上海)有限公司 Il-22二聚体在制备静脉注射药物中的应用
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
HRP20221233T1 (hr) 2014-03-14 2022-12-09 Biomolecular Holdings Llc Spojevi korisni u pripravi hibridnog imunoglobina koji sadrži nepeptidilnu vezu
EP3442562B1 (de) 2016-04-15 2022-09-21 Evive Biotechnology (Shanghai) Ltd Ein il-22-dimer zur verwendung in der behandlung der nekrotisierenden enterokolitis
EP3526248A4 (de) 2016-10-17 2020-07-08 Musc Foundation for Research Development Zusammensetzungen und verfahren zur behandlung von läsionen des zentralnervensystems
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
EP3615569A1 (de) 2017-04-25 2020-03-04 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antikörper und verfahren zur diagnose und behandlung von epstein-barr-virus-infektionen
CN111094334A (zh) 2017-07-19 2020-05-01 美国卫生与公众服务部 用于诊断和治疗乙肝病毒感染的抗体和方法
CN107653261A (zh) * 2017-10-19 2018-02-02 昆明理工大学 利用啤酒酵母MF‑α介导重组蛋白分泌的植物表达载体
US11339221B2 (en) 2017-11-01 2022-05-24 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use
WO2019213416A1 (en) 2018-05-02 2019-11-07 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
WO2021211493A1 (en) 2020-04-15 2021-10-21 Genentech, Inc. Copper loss mitigation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL82935A0 (en) * 1986-08-12 1987-12-20 Phillips Petroleum Co Secretion of heterologous proteins from yeast
EP0257115A1 (de) * 1986-08-21 1988-03-02 Heineken Technisch Beheer B.V. Durch rekombinante DNS-Technologie konstruierte amylolytische enzymproduzierende Mikroorganismen und ihre Verwendung in Gärungsverfahren
EP0260404B1 (de) * 1986-08-21 1995-05-31 VAN DEN BERG, Robert Durch rekombinante DNS-Technologie konstruierte amylolytische enzymproduzierende Mikroorganismen und ihre Verwendung in Gärungsverfahren

Also Published As

Publication number Publication date
DE68927344T2 (de) 1997-02-20
GR3022124T3 (en) 1997-03-31
EP0394538A1 (de) 1990-10-31
EP0394538B1 (de) 1996-10-16
DE394538T1 (de) 1991-04-11
GR910300058T1 (en) 1991-11-15
ES2038579T3 (es) 1997-02-16
ES2038579T1 (es) 1993-08-01
DE68927344D1 (de) 1996-11-21
CA2015077A1 (en) 1990-10-28
JPH03143385A (ja) 1991-06-18
CA2015077C (en) 2000-07-25

Similar Documents

Publication Publication Date Title
DE68927344T2 (de) Hefezellen der Gattung-Schwanniomyces
DK82293A (da) Normalt sporulerende bacillus uden evne til at udskille subtilisin eller neutral protease, kulturer deraf og fremgangsmaade til fremstilling af heterologe proteiner dermed
ES8602119A1 (es) Metodo para preparar inmunoglobulinas en celulas hospedantes recombinantes
DE69333766D1 (de) Herstellung von phytat-degradierenden enzymen in trichoderma
NO179106C (no) Fremgangsmåte for fremstilling av og ekspresjonssystem som koder for og kan uttrykke et rekombinant proteinkompleks med humanfaktor V111:C-aktivitet
ATE79403T1 (de) Herstellung von thrombin-inhibitoren.
AU3802595A (en) Tripeptidyl aminopeptidase
AU8258591A (en) Human mk gene and protein sequence
AU621810B2 (en) Amylolytic enzymes producing microorganisms, constructed by recombinant DNA technology and their use for fermentation processes
EP0320806A3 (de) An T-Zellenaktivierung gebundenes Gen
NO984491D0 (no) SCF-analogpreparater og fremgangsmÕte for fremstilling av disse
DE59712554D1 (de) Rekombinante expression von s-layer-proteinen
NO911557L (no) Fremgangsmaate for fremstilling av fremmedproteiner i streptomyceter.
DE3782560D1 (de) Hefestaemme zur expression fremder gene.
AU2253288A (en) Expression vectors for the synthesis of proteins and plasmid replicons and sequence cassettes for use in constructing such vectors
DE3682166D1 (de) Herstellung von insektizidprotein von bacillus thuringiensis subsp. aizawai ipl durch die expression von insektizidprotein-gen in wirtszellen.

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee